Intravenous administration of rADAMTS13 enhances neovascularization, promotes vascular remodeling, and improves neurological functions after stroke. (A) Representative images and quantification of CD31⁺ microvessels in WT mice treated with intravenous vehicle rADAMTS13 or rADAMTS13 in combination with VWF at 14 days after stroke. Scale bar = 100 μm. Values are mean ± SD. One-way ANOVA followed by Bonferroni multiple comparison test. n = 6 per group, *P < .05. (B) Representative in vivo multiphoton microscopic images of cortical capillaries with IV injected FITC-dextran (MW = 2 000 000 Da) and quantification of perfused capillary length in WT mice treated with intravenous vehicle rADAMTS13 or rADAMTS13 in combination with VWF at 14 days after stroke. Scale bar = 100 μm. Values are mean ± SD. One-way ANOVA followed by Bonferroni multiple comparison test. n = 6 per group, *P < .05. (C) Representative in vivo multiphoton microscopic images of IV injected FITC-dextran (MW = 40 000 Da) leakage from cortical vessels and quantification of the PS product of FITC-dextran in WT mice treated with intravenous vehicle rADAMTS13 or rADAMTS13 in combination with VWF at 14 days after stroke. Scale bar = 100 μm. Values are mean ± SD. One-way ANOVA followed by Bonferroni multiple comparison test. n = 6 per group, *P < .05. (D-F) Beam-walking and tape removal tests in WT mice treated with intravenous vehicle or rADAMTS13. Mice were subjected to stroke and treated with vehicle or rADAMTS13 on day 7. Values are mean ± SD. Unpaired, 2-tailed Student t test. n = 8 per group, *P < .05.